Radiopharmaceutical company raises funds

Country

Germany

A German radiopharmaceutical company has raised €90 million to complete development and commercialise a radionuclide therapy for cancer as well as build its oncology pipeline. ITM Isotopen Technologien München AG is conducting a Phase 3 trial of Lu-Edotreotide in patients with gastroenteropancreatic neuroendocrine tumours, which are rare tumours of the pancreas and parts of the gastrointestinal tract.